e-learning
resources
Milan 2017
Sunday, 10.09.2017
Mesothelioma and malignant pleural disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of multiple serum and pleural fluid biomarkers for the diagnosis of Malignant Pleural Mesothelioma
D. Neville (Portsmouth, United Kingdom)
Source:
International Congress 2017 – Mesothelioma and malignant pleural disease
Session:
Mesothelioma and malignant pleural disease
Session type:
Poster Discussion
Number:
1585
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Neville (Portsmouth, United Kingdom). Comparison of multiple serum and pleural fluid biomarkers for the diagnosis of Malignant Pleural Mesothelioma. 1585
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Optimizing invasive ventilation for SMA type 1 children who are receiving the gene therapy
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Pleural fluid, serum β-HCG levels and pleural fluid/serum β-HCG ratio for the discrimination of malignant and benign pleural effusions
Source: Eur Respir J 2003; 22: Suppl. 45, 60s
Year: 2003
Expression of YKL-40 and MIP-1a proteins in exudates and transudates: Biomarkers for differential diagnosis of pleural effusions?
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Cytology of pleural fluid versus histopathology of the pleura in the diagnosis of malignant pleural effusions
Source: Eur Respir J 2006; 28: Suppl. 50, 775s
Year: 2006
Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma
Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Year: 2013
Accuracy of pleural fluid c-reactive protein in differentiating between tuberculous and malignant pleural effusions: a meta-analysis
Source: International Congress 2019 – Tuberculosis and comorbidities
Year: 2019
Pleural fluid leptin level for the differential diagnosis of pleural effusion
Source: Eur Respir J 2006; 28: Suppl. 50, 343s
Year: 2006
Pleural fluid procalcitonin levels in identifying pleural effusions due to infection
Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections
Year: 2009
Utility of pleural fluid for predictive marker testing in malignant pleural effusion
Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications
Year: 2020
Correlation between pleural fluid cytological yield and pleural tumour burden in malignant pleural effusions
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
Value of thoracoscopic pleural brush in the diagnosis of exudative pleural effusion
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014
Evaluation of pleural fluid clot histology in the diagnosis of pleural malignancy
Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours
Year: 2008
Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Malignant pleural effusions: diagnosis and management
Source: International Congress 2017 – PG5 Pleural disease management
Year: 2017
Malignant pleural effusions: from the diagnosis to the management
Source: International Congress 2015 – ME2 Malignant pleural effusions: from diagnosis to management
Year: 2015
Management of malignant pleural effusions
Source: ERS Skills course: Multi-disciplinary care in thoracic oncology
Year: 2019
Management of malignant pleural effusions
Source: Guideline 2001
Year: 2001
Management of malignant pleural effusions
Source: Eur Respir J 2001; 18: 402-419
Year: 2001
Validity of Pleural Fluid Protein in differentiating Tuberculous from Malignant Pleural Effusion
Source: International Congress 2019 – Pleural infection and complicated pneumonia
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept